Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Other hematologic neoplasm 2Myeloid 1Lymphoid 1Dermatologic 1

Conditions

Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Sarcoma, Myeloid 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Leukemia, Biphenotypic, Acute 1Blast Crisis 1

Interventions

Cyclophosphamide 53fludarabine phosphate 52Peripheral Blood Stem Cell Transplantation 52Busulfan 39Tacrolimus 36Mycophenolic Acid 32Methotrexate 31Cyclosporine 31Antilymphocyte Serum 31Filgrastim 26Whole-Body Irradiation 25Cytarabine 24Radiotherapy 21Methylprednisolone 20Cord Blood Stem Cell Transplantation 18Melphalan 17Imatinib Mesylate 17Etoposide 16Flow Cytometry 12Thiotepa 11fludarabine 10Dasatinib 10Therapeutics 9Sirolimus 9Granulocyte Colony-Stimulating Factor 9nilotinib 8sargramostim 7Psychiatric Rehabilitation 7Decitabine 7Prednisone 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Blast Crisis × Dexrazoxane × Myeloid × Clear all
NCT03589729 2026-05-22

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

M.D. Anderson Cancer Center

Phase 2 Recruiting
100 enrolled
MyeloidOther hematologic neoplasmSarcoma

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡